克拉斯
医学
内科学
肿瘤科
癌症
癌症研究
药理学
结直肠癌
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-09-13
卷期号:13 (11): OF1-OF1
标识
DOI:10.1158/2159-8290.cd-nb2023-0066
摘要
According to the latest update from KRYSTAL-1, adagrasib shows durable efficacy in patients with advanced, previously treated KRASG12C non-small cell lung cancer. At 2 years, approximately one in three patients were still alive, and no new toxicities emerged, indicating that the KRASG12C inhibitor's long-term safety is manageable.
科研通智能强力驱动
Strongly Powered by AbleSci AI